by Ken Gemmell | Mar 24, 2023
2019 – Exclusive Financial Advisor to B4Health on Sale of the Company to AMN Healthcare Services (NYSE:AMN) B4health a leading SAS service provider of web-based vendor management software systems for healthcare facilities such as hospitals and other healthcare...
by Ken Gemmell | May 9, 2023
Exclusive Financial Advisor to Altor Bioscience Corporation* on Second Sale of Preferred Stock 2006—Completed the second sale of Altor BioScience Corporation Preferred Stock to Sanderling, a leading biotech capital investor. Altor BioScience Corporation develops...
by Ken Gemmell | Apr 5, 2023
Exclusive Financial Advisor to Sanderling Ventures on Sale of Intellectual Property 2005—Completed the sale of a substantial portion of the intellectual property for Genteric, Inc., a seed stage developer of therapeutic protein drugs, to Altor BioScience Corporation...
by Ken Gemmell | Mar 24, 2023
Exclusive Financial Advisor to Altor Bioscience Corporation* on Sale of Preferred Stock 2005 — Completed the sale of Altor BioScience Corporation Series B-1 Preferred Stock to Sanderling, a leading biotech capital investor. “Altor is very pleased with the...
